RPRX - Royalty Pharma plc
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
RPRX price evolution
RPRX
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1764.64 | $843 | $477.01 | |
| Short term investments | $788.6 | $689.48 | $756.74 | |
| Net receivables | $24.9 | $23.58 | $22.23 | $36.65 |
| Inventory | ||||
| Total current assets | $1794.19 | $2579.11 | $1559.72 | $1274.19 |
| Long term investments | $15049.91 | $14566.68 | $15101.14 | |
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $15077.47 | $14571.17 | $15107.66 | |
| Total investments | $15838.51 | $15256.16 | $15857.87 | |
| Total assets | $18042.24 | $17656.58 | $16130.89 | $16381.85 |
| Current liabilities | ||||
| Accounts payable | $22.05 | $23.42 | $11.55 | $15.16 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1167.76 | $275.7 | $124.57 | $161.38 |
| Long term debt | $6610.44 | $7602.02 | $6139.38 | $6135.28 |
| Total noncurrent liabilities | $7629.06 | $6142.6 | $6136.19 | |
| Total debt | $7602.02 | $6139.38 | $6135.28 | |
| Total liabilities | $11172.36 | $11180.33 | $6267.17 | $6297.56 |
| Shareholders' equity | ||||
| Retained earnings | $2764.68 | $2378.25 | $2427.45 | $2517.58 |
| Other shareholder equity | -$0 | -$0 | -$0 | -$0 |
| Total shareholder equity | $9751.82 | $9863.72 | $10084.29 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $477.01 | $1710.75 | $1541.05 | $1008.68 |
| Short term investments | $756.74 | $717.04 | $1262.22 | $1053.26 |
| Net receivables | $36.65 | $36.6 | $68.31 | $39.17 |
| Inventory | ||||
| Total current assets | $1274.19 | $2554.91 | $2878.21 | $2696.9 |
| Long term investments | $15101.14 | $14228.93 | $14627.84 | $13266.13 |
| Property, plant & equipment | $12368.08 | |||
| Goodwill & intangible assets | $5.67 | $28.67 | ||
| Total noncurrent assets | $15107.66 | $14258.56 | $14637.65 | $13323.39 |
| Total investments | $15857.87 | $14945.97 | $15890.06 | $14319.39 |
| Total assets | $16381.85 | $16813.47 | $17515.87 | $16020.29 |
| Current liabilities | ||||
| Accounts payable | $15.16 | $7.91 | $5.62 | $29.38 |
| Deferred revenue | ||||
| Short long term debt | $997.51 | |||
| Total current liabilities | $161.38 | $1166.78 | $171.25 | $307.89 |
| Long term debt | $6135.28 | $6118.81 | $7096.07 | $5816.58 |
| Total noncurrent liabilities | $6136.19 | $6121.31 | $7096.07 | $5816.58 |
| Total debt | $6135.28 | $7116.32 | $7096.07 | $5816.58 |
| Total liabilities | $6297.56 | $11185.32 | $7267.32 | $6124.47 |
| Shareholders' equity | ||||
| Retained earnings | $2517.58 | $1964.69 | $2255.18 | $1920.63 |
| Other shareholder equity | -$0 | -$0 | $16.49 | $34.4 |
| Total shareholder equity | $10084.29 | $9525.37 | $10248.55 | $4818.78 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $564.69 | $537.27 | $567.98 | $596.07 |
| Cost of revenue | ||||
| Gross Profit | $537.27 | $567.98 | $596.07 | |
| Operating activities | ||||
| Research & development | $0.5 | $0.5 | $0.5 | |
| Selling, general & administrative | $54.71 | $57.65 | $59.19 | |
| Total operating expenses | -$170.38 | $267.64 | $641.75 | -$16.83 |
| Operating income | $269.63 | -$73.77 | $612.9 | |
| Income from continuing operations | ||||
| EBIT | $151.02 | $49.01 | $541.6 | |
| Income tax expense | ||||
| Interest expense | $72.94 | $49.01 | $44.23 | $47.26 |
| Net income | ||||
| Net income | $543.99 | $102 | $4.78 | $494.34 |
| Income (for common shares) | $102 | $4.78 | $494.34 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2354.55 | $2237.22 | $2289.46 | $2122.35 |
| Cost of revenue | ||||
| Gross Profit | $2354.55 | $2237.22 | $2289.46 | $2122.35 |
| Operating activities | ||||
| Research & development | $52 | $177.11 | $200.08 | $26.29 |
| Selling, general & administrative | $249.75 | $227.3 | $182.83 | $181.72 |
| Total operating expenses | $862.4 | $1930.15 | $858.75 | $526.95 |
| Operating income | $1492.15 | $307.06 | $1430.71 | $1595.4 |
| Income from continuing operations | ||||
| EBIT | $1322.02 | $230.79 | $785.87 | $1132.1 |
| Income tax expense | ||||
| Interest expense | $187.19 | $187.96 | $166.14 | $157.06 |
| Net income | ||||
| Net income | $1134.83 | $42.83 | $619.73 | $975.04 |
| Income (for common shares) | $1134.83 | $42.83 | $619.73 | $975.04 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $102 | $4.78 | $494.34 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $658.21 | $664.64 | $772.63 | |
| Investing activities | ||||
| Capital expenditures | -$50 | |||
| Investments | -$845.21 | -$86.65 | -$998.13 | |
| Total cash flows from investing | -$2172.53 | -$893.18 | -$86.65 | -$1000.17 |
| Financing activities | ||||
| Dividends paid | -$282.81 | -$94.94 | -$93.81 | -$89.34 |
| Sale and purchase of stock | -$80 | -$30.2 | ||
| Net borrowings | $1462.01 | -$1.6 | ||
| Total cash flows from financing | $619.11 | $1156.61 | -$212 | -$231.89 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $473.04 | $921.64 | $365.99 | -$459.44 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $1134.83 | $42.83 | $619.73 | $975.04 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | -$34.33 | -$25.07 | ||
| Stock-based compensation | ||||
| Total cash flows from operations | $2987.8 | $2143.98 | $2017.54 | $2034.63 |
| Investing activities | ||||
| Capital expenditures | -$12.4 | -$18.6 | ||
| Investments | -$2058.35 | -$1029.42 | -$1817.35 | -$2734.25 |
| Total cash flows from investing | -$2072.79 | -$1029.42 | -$1870.28 | -$2759.32 |
| Financing activities | ||||
| Dividends paid | -$358.33 | -$333.32 | -$285.18 | -$397.84 |
| Sale and purchase of stock | -$304.76 | $1908.74 | ||
| Net borrowings | -$1001.6 | -$1.35 | $1259.49 | $633.92 |
| Total cash flows from financing | -$2148.75 | -$944.86 | $385.11 | $1487.17 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1233.74 | $169.7 | $532.37 | $762.48 |
News
Fundamentals
| Market cap | $18.23B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 590.92M |
| Revenue | $2.27B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $1.15B |
| Revenue Q/Q | 5.29% |
| Revenue Y/Y | -2.51% |
| P/E ratio | 15.92 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 8.04 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $1.94 |
|---|---|
| ROA | 6.72% |
| ROE | N/A |
| Debt/Equity | 0.62 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.54 |
| Quick ratio | N/A |